Notice of Results

Cyprotex PLC ('Cyprotex')

Notification of interim results

4 September 2012 - Cyprotex (AIM:CRX), the specialist preclinical contract research organisation (CRO), will be publishing its interim results for the six months ended 30 June 2012 on Thursday 6 September 2012.

Tony Baxter, Chief Executive Officer, and John Dootson, Chief Financial Officer, will present the results to analysts at 9.30am at the offices of FTI Consulting, Holborn Gate, 26 Southampton Buildings, London,WC2A 1PB.

Enquiries:

Notes to Editors:

Cyprotex PLC

Cyprotex is the world's largest contract research organisation (CRO) specialising in the analysis of the Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADME Tox) properties of potential drugs, cosmetics, and agrochemicals and has worked with more than 700 partners ranging from small biotechs to large pharma companies. It is the only company in the world with in-house in vitro (test tube) and in silico (computer modelling) ADME Tox capabilities and provides support for a wide range of experimental and computational ADME-Tox and PK services, extending from early drug discovery through to IND submission. The company's core capabilities include high quality in vitro ADME screening services, mechanistic toxicology and high content toxicology screening services and predictive modelling using PBPK and QSAR techniques, including Cloe® PK for in vivo PK prediction. For more information see www.cyprotex.com.

Established in 1999, the company is based in Macclesfield, near Manchester in the UK, and Watertown, Boston in the US and is listed on the AIM market of the London Stock Exchange (CRX).